Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Driver mutations in myeloid and lymphoid cells point to multipotent progenitor origin of diverse histiocytic neoplasms. Local targets link to admitted publications; unresolved targets remain external evidence.
Recurrent BRAF mutations in Langerhans cell histiocytosis
10.1182/blood-2010-04-279083 · 2010 · External reference
Somatic activating ARAF mutations in Langerhans cell histiocytosis
10.1182/blood-2013-06-511139 · 2014 · External reference
MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis
10.1002/gcc.22247 · 2015 · External reference
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
10.1038/s41591-019-0653-6 · 2019 · External reference
Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study
10.1182/bloodadvances.2022007947 · 2023 · External reference
Recurrent CLTC::SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissue
10.1182/blood.2024025127 · 2024 · External reference
Recurrent ETV3::NCOA2 fusions and MAPK pathway mutations in indeterminate dendritic cell histiocytosis
202593439 · External reference
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
10.1182/blood-2016-01-690636 · 2016 · External reference
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms
10.1038/s41375-022-01613-1 · 2022 · External reference
BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups
10.1084/jem.20130977 · 2014 · External reference
Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults
10.1182/blood-2016-12-757823 · 2017 · External reference
Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells
10.1182/blood-2016-12-757377 · 2017 · External reference
Bone marrow–derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis
10.1182/blood.2020005209 · 2020 · External reference
High frequency of clonal hematopoiesis in Erdheim-Chester disease
10.1182/blood.2020005101 · 2021 · External reference
High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy
10.1182/bloodadvances.2019032367 · 2020 · External reference
Erdheim–Chester disease long-bone osteosclerosis can be reproduced with a xenografted mouse model and its pathogenesis may involve dysregulation of bone metabolism key cytokines
10.1111/bjh.18415 · 2022 · External reference
Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAF V600E
10.1182/bloodadvances.2022007519 · 2022 · External reference
Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells
10.1182/bloodadvances.2019000488 · 2020 · External reference
Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis
10.1182/bloodadvances.2021005442 · 2022 · External reference
High burden and pervasive positive selection of somatic mutations in normal human skin
10.1126/science.aaa6806 · 2015 · External reference
Hematopoietic stem and progenitor cells outside the bone marrow: where, when, and why
10.1016/j.exphem.2021.10.002 · 2021 · External reference
Hematopoietic stem and progenitor cells are present in healthy gingiva tissue
10.1084/jem.20200737 · 2021 · External reference
